text:
Using the MBGV GP, NP, and virion proteins, a method and composition for use in inducing an immune response which is protective against infection with MBGV in nonhuman primates is described.
1. A recombinant DNA construct comprising:
(i) a vector, and
(ii) at least one of the MBGV virus DNA fragments encoding any one of GP, NP, VP40, VP35, VP30, VP24, and GPΔTM.
2. A recombinant DNA construct according to
3. A recombinant DNA construct according to
4. A recombinant DNA construct according to
5. The recombinant DNA construct of
6. The recombinant DNA construct according to
7. The recombinant DNA construct according to
8. The recombinant DNA construct according to
9. The recombinant DNA construct according to
10. The recombinant DNA construct according to
11. The recombinant DNA construct according to
12. The recombinant DNA construct according to
13. The recombinant DNA construct according to
14. Self replicating RNA produced from the construct of any of
15. Infectious alphavirus particles produced from packaging the self replicating RNA of
16. A pharmaceutical composition comprising infectious alphavirus particles according to
17. A host cell transformed with a recombinant DNA construct according to
18. A host cell according to
19. A host cell according to
20. A method for producing MBGV virus proteins comprising culturing the cells according to
21. A method for producing MBGV proteins comprising culturing the cells according to
22. A vaccine for MBGV comprising viral particles containing one or more replicon RNA encoding one or more MBGV proteins selected from the group consisting of GP, NP, VP24, VP30, VP35, VP40, and GPΔTM.
23. A pharmaceutical composition comprising the self replication RNA of
24. A pharmaceutical composition comprising one or more recombinant DNA constructs chosen from the group consisting of pRep Mus GP, pRep Mus GPΔTM, pRep Mus NP, pRep Mus VP40, pRep Mus VP35, pRep Mus VP30, pRep Mus VP24 in a pharmaceutically acceptable amount, in a pharmaceutically accpetable carrier/and or adjuvant.
[0001] Marburg virus (MBGV) was first recognized in 1967, when an outbreak of hemorrhagic fever in humans occurred in Germany and Yugoslavia, after the importation of infected monkeys from Uganda (Martini and Siegert, 1971, Marburg Virus Disease. Berlin: Springer-Verlag; Smith et al., 1982, Lancet 1, 816-820). Thirty-one cases of MBGV hemorrhagic fever were identified that resulted in seven deaths. The filamentous morphology of the virus was later recognized to be characteristic, not only of additional MBGV isolates, but also of Ebola virus (EBOV) (Johnson et al., 1977, J. Virol. 71, 3031-3038; Smith et al., 1982, Lancet 1, 816-820; Pattyn et al., 1977, Lancet 1, 573-574). MBGV and EBOV are now known to be distinctly different lineages in the family Filoviridae, within the viral order Mononegavirales (Kiley et al., 1982, Intervirology 18, 24-32; Feldmann and Klenk, 1996, Adv. Virus Res. 47, 1-52).
[0002] Few natural outbreaks of MBGV disease have been recognized, and all proved self-limiting, with no more than two cycles of human-to-human transmission. However, the actual risks posed by MBGV to global health cannot be assessed because factors which restrict the virus to its unidentified ecological niche in eastern Africa, and those that limit its transmissibility, remain unknown (Feldmann and Klenk, 1996, supra). Concern about MBGV is further heightened by its known stability and infectivity in aerosol form (Belanov et al., 1996, Vopr. Virusol. 41, 32-34; Frolov and Gusev Iu, 1996, Vopr. Virusol. 41, 275-277). Thus, laboratory research on MBGV is necessarily performed at the highest level of biocontainment. To minimize future risk, our primary interest has been the identification of appropriate antigens and vaccine strategies that can provide immunity to MBGV.
[0003] Early efforts to demonstrate the feasibility of vaccination against MBGV were only partially successful, as inoculation with formalin-inactivated viruses only protected about half the experimental animals (guinea pigs or nonhuman primates) from fatal disease (Ignat'ev et al., 1991, Vopr. Virusol. 36, 421-423; Ignat'ev et al., 1996, J. Biotechnol. 44, 111-118). We recently demonstrated that the MBGV GP, cloned into a baculovirus vector and expressed as a soluble antigen to be administered in adjuvant, was sufficient to protect most but not all guinea pigs from lethal MBGV challenge (Hevey et al., 1997, Virology 239, 206-216). In addition, purified, 60Co-irradiated virus, administered in adjuvant, completely protected guinea pigs from challenge with either of two different strains of MBGV, thus setting a standard for future, more pragmatic, vaccine candidates (Hevey et al., 1997, supra). Experiences with EBOV vaccines have been similar to those with MBGV, reinforcing the difficulties of classical approaches (Lupton et al., 1980, Lancet 2, 1294-1295). Recent efforts to develop EBOV vaccines, using three distinctly different approaches (vaccinia recombinants, VEE replicon, and naked DNA) to achieve viral antigen expression in cells of vaccinated animals, showed that nucleoprotein (NP) as well as GP protected BALB/c mice (VanderZanden et al., 1998, Virology 245), whereas protection of guinea pigs by NP was unsuccessful (Gilligan et al., 1997, In: Brown, F., Burton, D., Doherty, P., Mekalanos, J., Norrby, E. (eds). 1997. Vaccines 97 Cold Spring Harbor Press. Cold Spring Harbor, N.Y.; Pushko et al., 1997, In: Brown, F., Burton, D., Doherty, P., Mekalanos, J., Norrby, E. (eds). 1997. Vaccines 97 Cold Spring Harbor Press. Cold Spring Harbor, N.Y.) or equivocal (Xu et al., 1998, Nat. Med. 4, 37-42).
[0004] Irrespective of how encouraging filovirus vaccine results may appear in guinea pigs or mice, protection of nonhuman primates is widely taken as the more definitive test of vaccine potential for humans. Low-passage viral isolates from fatal human cases of MBGV or EBOV tend to have uniform lethality in nonhuman primates, but not in guinea pigs or mice. Small animal models with fatal disease outcomes have been achieved only with a subset of filovirus isolates and only then by multiple serial passages in the desired host (Hevey et al., 1997, supra; Connolly et al., 1999, J. Infect. Dis. 179, suppl. 1, S203; Xu et al., 1998, supra; Bray et al., 1998, J. Infect. Dis. 178, 661-665). While highly useful for identification and initial characterization of vaccine candidates, guinea pig and murine models remain somewhat suspect with regard to the possibility that protection in such animals is easier to achieve than in nonhuman primates and, by inference, in humans. For example, with MBGV, peak viremias and viral titers in organs are more than 100 times higher in nonhuman primates than in guinea pigs.
[0005] Therefore, there is a need for an efficacious vaccine for MBGV useful for protecting humans against Marburg hemorrhagic fever.
[0006] The present invention satisfies the need discussed above. The present invention relates to a method and composition for use in inducing an immune response which is protective against infection with MBGV.
[0007] In this study a vaccine delivery system based on a Venezuelan equine encephalitis (VEE) virus replicon was used to identify candidate protective antigens in nonhuman primates. In this vaccine strategy, a gene coding for a protein of interest is cloned in place of the VEE virus structural genes; the result is a self-replicating RNA molecule that encodes its own replicase and transcriptase functions, and in addition makes abundant quantities of mRNA encoding the foreign protein. When replicon RNA is transfected into eukaryotic cells along with two helper RNAs that express the VEE structural proteins (glycoproteins and nucleocapsid), the replicon RNA is packaged into VEE virus-like particles by the VEE virus structural proteins, which are provided in trans. Since the helper RNAs lack packaging signals neccessary for further propagation, the resulting VEE replicon particles (VRPs) which are produced are infectious for one cycle but are defective thereafter. Upon infection of an individual cell with a VRP, an abortive infection occurs in which the infected cell produces the protein of interest in abundance, is ultimately killed by the infection, but does not produce any viral progeny (Pushko et al., 1997, Virology 239, 389-401). The VEE replicon is described in greater detail in U.S. Pat. No. 5,792,462 issued to Johnston et al. on Aug. 11, 1998.
[0008] Results shown here demonstrate that the VEE replicon is a potent tool for vaccination with MBGV antigens. Guinea pigs were protected by vaccination with packaged replicons that expressed GP, or by either of two replicons which expressed internal MBGV antigens (NP and VP35). GP expressed from the VEE replicon elicited an even more robust immunity than was achieved previously with a baculovirus-produced soluble GP administered in adjuvant. When results were extended to nonhuman primates, complete protection with GP was demonstrated. The data shown here constitute the most emphatic proof to date that an efficacious vaccine for MBGV is feasible, and define candidate antigens for such a vaccine.
[0009] Therefore, it is one object of the present invention to provide a VEE virus replicon vector comprising a VEE virus replicon and a DNA fragment encoding any of the MBGV GP, NP, VP40, VP35, VP30, and VP24, and GPΔTM, a GP deletion mutant from which the C-terminal 39 amino acids encoding the transmembrane region and cytoplasmic tail of MBGV GP were removed.
[0010] It is another object of the present invention to provide a self replicating RNA comprising the VEE virus replicon and any of the MBGV GP, GPΔTM, NP, VP40, VP35, VP30, and VP24 described above.
[0011] It is another object of the present invention to provide infectious VEE virus replicon particles produced from the VEE virus replicon RNA described above.
[0012] It is further an object of the invention to provide an immunological composition for the protection of mammals against MBGV infection comprising VEE virus replicon particles containing nucleic acids encoding any of the MBGV GP, GPΔTM, NP, VP40, VP35, VP30, and VP24 or a combination of different VEE virus replicons each containing nucleic acids encoding a different MBGV protein from any of MBGV GP, GPΔTM, NP, VP40, VP35, VP30, and VP24.
[0013] These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description and appended claims, and accompanying drawings where:
[0014]FIG. 1. Indirect immunofluorescence of Vero cells infected with packaged VEE replicons expressing the indicated antigens.
[0015]FIG. 2. Immunoprecipitation of MBGV proteins expressed from an alphavirus replicon in Vero cells using convalescent guinea pig polyclonal anti-MBGV serum. Lane 1, cell lysate from Vero cells infected with MBGV GP replicon; lane 2, cell lysate from Vero cells infected with MBGV GPΔTM replicon; lane 3, supernatant from Vero cells infected with MBGV GPΔTM replicon; lanes 4-6, cell lysate from Vero cells infected with various clones of MBGV NP replicon; lanes 7-8, cell lysate from Vero cells infected with various clones of MBGV VP40 replicon; lane 9, sucrose gradient-purified 35S-labeled MBGV, * an unidentified 46-50 KDa protein observed in virion preparations.
[0016]FIG. 3. Anti-MBGV ELISA titers of cynomolgus monkeys after three inoculations with recombinant replicon 17 days before or after challenge with MBGV. Prechallenge samples were obtained 17 days before challenge, while postchallenge samples were obtained 17 days after challenge. GP, animals inoculated with VEE replicons expressing MBGV GP; NP, animals inoculated with VEE replicon expressing MBGV NP; GP+NP, animals inoculated with a mixture of VEE replicons expressing either MBGV GP or NP; Flu HA, animals inoculated with VEE replicon expressing influenza HA. Numbers inside each symbol represent the same individual in each group. Symbols filled in with cross hatch marks signify animals that died from infection.
[0017]FIG. 4. Viremia level in cynomolgus monkeys inoculated with alphavirus replicons followed by challenge with MBGV (Musoke). Animals vaccinated with VEE replicons expressing MBGV GP; ♦ animals vaccinated with VEE replicons expressing MBGV NP; ▪, animals vaccinated with a mixture of VEE replicons which expressed either MBGV GP or NP; Δ, animals vaccinated with VEE replicons expressing influenza HA. Open symbols represent animals that died. Closed symbols represent animals that lived. Dotted line notes the lower limit of detection of this plaque assay (1.7Log10 PFU/ml).
[0018]FIG. 5. Serum AST levels in VEE replicon inoculated cynomolgus macaques after challenge with MBGV (Musoke). The one animal (of six) vaccinated with VEE replicons expressing MBGV GP that exhibited AST abnormality at any time point. ♦, animals vaccinated with VEE replicons expressing MBGV NP; Δ, animals vaccinated with VEE replicon expressing influenza HA. Open symbols represent animals that died. Closed symbols represent animals that lived. Dotted line demarks 88 U/L, which is the mean (38 U/L) plus three standard deviations of pre-bleed values from the 12 monkeys in this experiment.
[0019]FIG. 6: Schematic of pRep Mus GP.
[0020]FIG. 7: Schematic of pRep Mus GPΔTM.
[0021]FIG. 8: Schematic of pRep Mus NP.
[0022]FIG. 9: Schematic of pRep Mus VP40.
[0023]FIG. 10: Schematic of pRep Mus VP35.
[0024]FIG. 11: Schematic of pRep Mus VP30.
[0025]FIG. 12: Schematic of pRep Mus VP24.
[0026] In the description that follows, a number of terms used in recombinant DNA, virology and immunology are extensively utilized. In order to provide a clearer and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.
[0027] Filoviruses. The filoviruses (e.g. Marburg virus, MBGV) cause acute hemorrhagic fever characterized by high mortality. Humans can contract filoviruses by infection in endemic regions, by contact with imported primates, and by performing scientific research with the virus. However, there currently are no available vaccines or effective therapeutic treatments for filovirus infection. The virions of filoviruses contain seven proteins which include a surface glycoprotein (GP), a nucleoprotein (NP), an RNA-dependent RNA polymerase (L), and four virion structural proteins (VP24, VP30, VP35, and VP40). Little is known about the biological functions of these proteins and it is not known which antigens significantly contribute to protection and should therefore be used to induce an immune response by an eventual vaccine candidate.
[0028] Replicon. A replicon is equivalent to a full length virus from which all of the viral structural proteins have been deleted. A multiple cloning site can be cloned into the site previously occupied by the structural protein genes. Virtually any heterologous gene may be cloned into this cloning site. Transcription of the RNA from the replicon yields an RNA capable of initiating infection of the cell identical to that seen with the full-length infectious virus clone. However, in lieu of the viral structural proteins, the heterologous antigen is expressed. This system does not yield any progeny virus particles because there are no viral structural proteins available to package the RNA into particles.
[0029] Particles which appear structurally identical to virus particles can be produced by supplying structural proteins for packaging of the replicon RNA in trans. This is typically done with two helpers also called defective helper RNAs. One helper consists of a full length infectious clone from which the nonstructural protein genes and the glycoprotein genes are deleted. The helper retains only the terminal nucleotide sequences, the promoter for subgenomic mRNA transcription and the sequences for the viral nucleocapsid protein. The second helper is identical to the first except that the nucleocapsid gene is deleted and only the glycoprotein genes are retained. The helper RNA's are transcribed in vitro and co-transfected with replicon RNA. Because the replicon RNA retains the sequences for packaging by the nucleocapsid protein, and because the helpers lack these sequences, only the replicon RNA is packaged by the viral structural proteins and released from the cell. The particles can then by inoculated into animals similar to parent virus. The replicon particles will initiate only a single round of replication because the helpers are absent, they produce no progeny virus particles, and express only the viral nostructural proteins and the product of the heterologous gene cloned in place to the structural proteins.
[0030] The VEE virus replicon is a genetically reorganized version of the VEE virus genome in which the structural proteins genes are replaced with a gene from an immunogen of interest, in this invention, the MBGV virion proteins. The result is a self replicating RNA (replicon) that can be packaged into infectious particles using defective helper RNAs that encode the glycoprotein and capsid proteins of the VEE virus.
[0031] Subject. Includes both human, animal, e.g., horse, donkey, pig, guinea pig, mouse, hamster, monkey, chicken, bats, birds and insects such as mosquito.
[0032] In one embodiment, the present invention relates to a recombinant DNA molecule that includes a VEE replicon and a DNA sequence encoding any of MBGV virion proteins GP, GPΔTM, NP, VP40, VP35, VP30, VP24. The sequences encoding the Marburg proteins GP, GPΔTM, NP, VP40, VP35, VP30, VP24 corresponding to nucleotides 104-11242 of the Genbank sequence is presented in SEQ ID NO:1; the GP DNA fragment extends from nucleotide 5932 to 8033, of which nucleotides 5940-7985 encode the protein identified in SEQ ID NO:2; the GPΔTM DNA fragment, a GP deletion mutant from which the C-terminal 39 amino acids encoding the transmembrane region and cytoplasmic tail of MBGV GP were removed, extends from nucleotides 5933 to 7869, of which nucleotides 5940-7871 encode the protein; NP, identified in SEQ ID NO:3, is encoded by the DNA fragment extending from nucleotides 104 to 2195; VP40 DNA fragment extends from nucleotide 4564 to 5958, of which nucleotides 4567-5416 encode the protein identified in SEQ ID NO:4; VP35 DNA fragment extends from nucleotide 2938 to 4336, of which nucleotides 2944-3933 encode the protein identified in SEQ ID NO:5; VP30 DNA fragment extends from nucleotide 8861 to 9979, of which nucleotides 8864-9697 encode the protein identified in SEQ ID NO:6; VP24 DNA fragment extends from nucleotide 10182 to 11242, of which nucleotides 10200-10961 encode the protein identified in SEQ ID NO:7.
[0033] When the DNA sequences described above are in a replicon expression system, such as the VEE replicon described above, the proteins can be expressed in vivo. The DNA sequence for any of the MBGV virion proteins described above can be cloned into the multiple cloning site of a replicon such that transcription of the RNA from the replicon yields an infectious RNA containing the sequence(s) which encodes the MBGV virion protein or proteins of interest. Use of helper RNA containing sequences necessary for encapsulation of the viral transcript will result in the production of viral particles containing replicon RNA which are able to infect a host and initiate a single round of replication resulting in the expression of the MBGV virion proteins. Such replicon constructs include, for example, VP24 cloned into a VEE replicon, pRep Mus VP24, VP30 cloned into a VEE replicon, pRep Mus VP30, VP35 cloned into a VEE replicon, pRep Mus VP35, and VP40 cloned into a VEE replicon, pRep Mus VP40, NP cloned into a VEE replicon, pRep Mus NP, GP cloned into a VEE replicon, pRep Mus GP, GPΔTM cloned into a VEE replicon, pRep Mus GPΔTM. The sequences encoding the MBGV proteins were cloned into the replicon vector by methods known in the art and described below in Materials and Methods. Schematic diagrams of the resulting constructs are shown in the Figures. The VEE constructs containing Marburg proteins can be used as a DNA vaccine, or for the production of RNA molecules as described below.
[0034] In another embodiment, the present invention relates to RNA molecules resulting from the transcription of the constructs described above. The RNA molecules can be prepared by in vitro transcription using methods known in the art and described in the Examples below. Alternatively, the RNA molecules can be produced by transcription of the constructs in vivo, and isolating the RNA. These and other methods for obtaining RNA transcripts of the constructs are known in the art. Please see Current Protocols in Molecular Biology. Frederick M. Ausubel et al. (eds.), John Wiley and Sons, Inc. The RNA molecules can be used, for example, as a direct RNA vaccine, or to transfect cells along with RNA from helper plasmids, one of which expresses VEE glycoproteins and the other VEE capsid proteins, as described above, in order to obtain replicon particles.
[0035] In a further embodiment, the present invention relates to host cells stably transformed or transfected with the above-described recombinant DNA constructs. The host cell can be prokaryotic (for example, bacterial), lower eukaryotic (for example, yeast or insect) or higher eukaryotic (for example, all mammals, including but not limited to mouse and human). Both prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences when appropriate control sequences which are compatible with the designated host are used. Among prokaryotic hosts, E. coli is most frequently used. Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors compatible with prokaryotic hosts are commonly derived from, for example, pBR322, a plasmid containing operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, which also contain sequences conferring antibiotic resistance markers. These markers may be used to obtain successful transformants by selection. Please see e.g., Maniatis, Fitsch and Sambrook, Molecular Cloning A Laboratory Manual (1982) or DNA Cloning, Volumes I and II (D. N. Glover ed. 1985) for general cloning methods. The DNA sequence can be present in the vector operably linked to a sequence encoding an IgG molecule, an adjuvant, a carrier, or an agent for aid in purification of MBGV virion proteins, such as glutathione S-transferase. The recombinant molecule can be suitable for transfecting eukaryotic cells, for example, mammalian cells and yeast cells in culture systems. Saccharomyces cerevisiae, Saccharomyces carlsbergensis, and Pichia pastoris are the most commonly used yeast hosts, and are convenient fungal hosts. Control sequences for yeast vectors are known in the art. Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), such as CHO cells, vero cells, and COS cells to name a few. Suitable promoters are also known in the art and include viral promoters such as that from SV40, Rous sarcoma virus (RSV), adenovirus (ADV), bovine papilloma virus (BPV), and cytomegalovirus (CMV). Mammalian cells may also require terminator sequences and poly A addition sequences; enhancer sequences which increase expression may also be included, and sequences which cause amplification of the gene may also be desirable. These sequences are known in the art.
[0036] The transformed or transfected host cells can be used as a source of DNA sequences described above. When the recombinant molecule takes the form of an expression system, the transformed or transfected cells can be used as a source of the protein cloned into the VEE replicon, or a source of RNA transcribed from the replicon as described above, or a source of replicon particles.
[0037] In a further embodiment, the present invention relates to a method of producing the recombinant or fusion protein which includes culturing the above-described host cells, under conditions such that the DNA fragment is expressed and the recombinant or fusion protein is produced thereby. The recombinant or fusion protein can then be isolated using methodology well known in the art. The recombinant or fusion protein can be used as a vaccine for immunity against infection with MBGV or as a diagnostic tool for detection of MBGV infection. The transformed host cells can be used to analyze the effectiveness of drugs and agents which inhibit MBGV virus function, such as host proteins or chemically derived agents or other proteins which may interact with the virus to inhibit its replication or survival.
[0038] In another embodiment, the present invention relates to a MBGV vaccine comprising one or more replicon particles derived from one or more replicons encoding one or more MBGV virion proteins. The present invention relates to a method for providing immunity against MBGV virus said method comprising administering one or more replicon particles containing any combination of the MBGV virion proteins to a subject such that a protective immune reaction is generated. Even though the MBGV strain Musoke was used in the examples below, it is expected that protection would be afforded using virion proteins from other MBGV strains, as well as significant cross protection between strains.
[0039] Vaccine formulations of the present invention comprise an immunogenic amount of a replicon particle, resulting from one of the replicon constructs described above, or a combination of replicon particles as a multivalent vaccine, in combination with a pharmaceutically acceptable carrier. An �immunogenic amount� is an amount of the replicon particles sufficient to evoke an immune response in the subject to which the vaccine is administered. An amount of from about 105 to 108 or more replicon particles per dose with one to three doses one month apart is suitable, depending upon the age and species of the subject being treated. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution.
[0040] Administration of the replicon particles disclosed herein may be carried out by any suitable means, including both parenteral injection (such as intraperitoneal, subcutaneous, or intramuscular injection), by in ovo injection in birds, orally and by topical application of the virus (typically carried in the pharmaceutical formulation) to an airway surface. Topical application of the virus to an airway surface can be carried out by intranasal administration (e.g. by use of dropper, swab, or inhaler which deposits a pharmaceutical formulation intranasally). Topical application of the virus to an airway surface can also be carried out by inhalation administration, such as by creating respirable particles of a pharmaceutical formulation (including both solid particles and liquid particles) containing the replicon as an aerosol suspension, and then causing the subject to inhale the respirable particles. Methods and apparatus for administering respirable particles of pharmaceutical formulations are well known, and any conventional technique can be employed.
[0041] When the replicon RNA or DNA is used as a vaccine, the replicon RNA or DNA can be administered directly using techniques such as delivery on gold beads (gene gun), delivery by liposomes, or direct injection, among other methods known to people in the art. Any one or more constructs or replicating RNA described above can be use in any combination effective to illicit an immunogenic response in a subject. Generally, the nucleic acid vaccine administered may be in an amount of about 1-5 ug of nucleic acid per dose and will depend on the subject to be treated, capacity of the subject's immune system to develop the desired immune response, and the degree of protection desired. Precise amounts of the vaccine to be administered may depend on the judgement of the practitioner and may be peculiar to each subject and antigen.
[0042] The vaccine may be given in a single dose schedule, or preferably a multiple dose schedule in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months. Examples of suitable immunization schedules include: (i) 0, 1 months and 6 months, (ii) 0, 7 days and 1 month, (iii) 0 and 1 month, (iv) 0 and 6 months, or other schedules sufficient to elicit the desired immune responses expected to confer protective immunity, or reduce disease symptoms, or reduce severity of disease.
[0043] The following MATERIALS AND METHODS were used in the examples that follow.
[0044] Cell Cultures and Viruses
[0045] Vero E6 (Vero C1008, ATCC CRL 1586), Vero 76 (ATCC CRL 1587), and BHK (ATCC CCL 10) cells were grown in minimal essential medium with Earle's salts supplemented with 10% fetal bovine serum and gentamicin (50 μg/ml). MBGV (strain Musoke) was isolated from a human case in 1980 in Kenya (Smith et al., 1982, Lancet 1, 816-820), and a derivative of this virus (six passages in Vero 76 cells) was used to challenge the cynomolgus monkeys. The MBGV (Musoke) that was adapted for guinea pig lethality and plaque-picked three times was described previously (Hevey et al., 1997, Virology 239, 206-210).
[0046] Construction of Recombinant VEE Replicons
[0047] MBGV gene clones pGem-GP, pGem-NP, pTM1-VP40, pTM1-VP35, pTM1-VP30, and pTM1-VP24 were generously provided by Heinz Feldmann and Anthony Sanchez (Centers for Disease Control and Prevention, Atlanta, Ga.) (Will et al., 1993, J. Virol. 67, 1203-1210; Sanchez et al., 1992, J. Gen. Virol. 73, 347-357; Feldman et al., 1992, Virus Res. 24, 1-19). VEE replicon and shuttle vector as well as the replicons that express Lassa virus NP and Flu HA were previously described (Pushko et al., 1997, Virology 239, 289-401). The MBGV GP gene from pGem-GP was excised with Sal I and subcloned into the Sal I site of the shuttle vector by using standard techniques (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual. 2 ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor). A clone with the MBGV GP gene in the correct orientation was excised with Apa I and Not I and this fragment was cloned into the Apa I and Not I sites of the VEE replicon plasmid.
[0048] Construction of pBluescript-KS(+)-GPΔTM, a deletion mutant of MBGV from which the C-terminal 39 amino acids (transmembrane region and cytoplasmic tail) of MBGV GP were removed, was previously described (Hevey et al., 1997, supra). Here, the MBGV GPΔTM gene was excised from pBluescript-KS(+) with Hind III, and the resulting fragment ligated into the Hind III site of the shuttle vector. MBGV GPΔTM gene was excised from the shuttle vector using Cla I, and the resulting fragment ligated into the VEE replicon plasmid.
[0049] The MBGV NP gene was amplified by PCR performed with 1 ng of pGem NP as template DNA, 1 μg each of forward (5′-CCG ACC ATG GAT TTA CAC AGT TTG TTG G-3′, SEQ ID NO:8) and reverse primer (5′-CTA GCC ATG GCT GGA CTA CAA GTT CAT CGC-3′ SEQ ID NO:9), and AmpliTaq polymerase (GeneAmp PCR reagent kit, Perkin Elmer, Branchburg, N.J.). The primers contained an NcoI recognition sequence at the 3′ terminus end (5-10 inclusive for both the forward and reverse primers). The reaction conditions were: 40 cycles of 94� C. for 45 sec, 50� C. for 45 sec, and 72� C. for 1 min., followed by a final extension step at 72� C. for 5 min. The product was cloned into the pCR�II (InVitrogen, Carlsbad, Calif.) vector, excized with Eco RI, then subcloned into the shuttle vector using Eco RI sites. The MBGV NP gene was excised with Cla I and ligated into the VEE replicon plasmid.
[0050] The MBGV VP40, VP35, VP30, and VP24 genes were excised from pTMl with Bam HI and ligated into the Bam HI site of the shuttle vector. These MBGV genes were then excised from shuttle vectors using either Cla I (VP35, VP30, and VP24) or Apa I and Not I (VP40) and ligated into the VEE replicon plasmid.
[0051] Packaging of Replicons into VEE-Like Particles and Determination of Replicon Titer
[0052] Replicon RNAs were packaged into VRPs as described previously (Pushko et al., 1997, Virology 239, 389-401). Briefly, BHK cells were cotransfected with RNA transcribed in vitro from the replicon plasmid and from two helper plasmids, one of which expressed VEE glycoproteins and the other VEE capsid protein. The cell culture supernatant was harvested approximately 30 h after transfection and the replicon particles were concentrated and partially purified by pelleting through a 20% sucrose cushion (SW28 rotor, 25,000 rpm, 4 h), after which they were resuspending in 1 ml PBS. To assay titers of packaged replicons, Vero cells (105 cells per well in eight-chamber slides, Labtek slides, Nunc Inc.) were infected with serial dilutions of the replicon particles and incubated for 16-18 h at 37� C. to allow for expression of the MBGV genes. After rinsing and fixating with acetone, antigen-positive cells were identified by indirect immunofluorescence assay (IFA) as described previously (Schmaljohn et al, 1995, Virology 206, 963-972). The antibodies used included MAbs specific for MBGV GP (II-7C11), NP (III-5F8), VP40 (III-1H11), VP35 (XBC04-BG06), and VP30 (III-5F11 and 5F12) (Hevey et al., 1997, supra). To detect VP24 antigen, a monkey anti-MBGV serum was used, a monkey anti-Lassa serum was used to detect expression of Lassa NP in cells, and influenza HA was detected with serum from a mouse immunized with a VEE replicon expressing influenza HA (provided by Dr. Mary Kate Hart, USAMRIID).
[0053] Immunoprecipitation and Gel Electrophoresis of Proteins Expressed by VEE Replicons
[0054] Expressed MBGV antigens were immunoprecipitated and analyzed by gel electrophoresis as described previously (Hevey et al., 1997, supra). Briefly, Vero cells were infected (MOI≧3) with VRP expressing a single MBGV antigen. Complete medium was replaced 16-18 h postinfection by methionine- and cysteine-free medium for 1 h, and monolayers were then labeled with 35S-methionine and cysteine for 4 h. Convalescent guinea pig anti-MBGV (group 1, Table 5, in Hevey et al., 1997, supra) was used to immunoprecipitate MBGV-specific proteins from the resulting cell lysates.
[0055] Vaccination of Guinea Pigs with VEE Replicons Expressing MBGV Proteins
[0056] Inbred strain 13 guinea pigs (maintained as a colony at USAMRIID) were inoculated subcutaneously with 106 focus-forming units (FFU) of VRP in a total volume of 0.5 ml administered at two dorsal sites. Guinea pigs were anesthetized, bled, and those that received two or three doses of replicon inoculated (as described for the first vaccine dose) 28 days after the primary vaccination. Guinea pigs were anesthetized and bled again 28 days later, and animals that received three doses of replicons were inoculated, as described above. Animals were anesthetized and bled 21 days later, and challenged 7 days after the last bleed with 103.0 plaque forming units (PFU) (ca. 2000 LD50) guinea pig adapted MBGV. Animals were examined daily for signs of illness. Heparinized plasma was obtained from the retroorbital sinus of anesthetized animals 7 days postinfection for assay of viremia. Surviving guinea pigs were observed for at least 30 days after challenge, then anesthetized and exsanguinated. Viremia titers was measured by plaque assay on Vero E6 cells.
[0057] Vaccination of Cynomolgus Monkeys with Replicons
[0058] Twelve cynomolgus macaques (Macaca fascicularis), 11 females and 1 male, ranging from 2.8 to 4.5 Kg, were inoculated subcutaneously with 107 FFU of VRP in a total volume of 0.5 ml at one site. Monkeys were anesthetized with ketamine, bled, and inoculated (as described for the first vaccine dose) 28 days after the primary injection, and again 28 days after the second. Animals were anesthetized and bled 21 days after the third vaccine dose, then were challenged 14 days later with 103.9 PFU MBGV subcutaneously. Here and in guinea pig experiments, the inoculum was back-titrated to ensure proper dose delivery. Animals were examined daily by the attending veterinarian for signs of illness, and given buprenorphine (Buprenex) at a dosage of 0.01 mg/kg body weight, to provide analgesia upon signs of distress. Of the unprotected animals, three succumbed abruptly, while one was euthanized in extremis. A detailed clinical evaluation, serum for viremia determination and blood chemistries, as well as EDTA blood was obtained from anesthetized animals 17 days before and 3, 5, 7, 10, 17, and 32 days postinfection. Viremia was measured by plaque assay on Vero E6 cells.
[0059] MBGV ELISA and Infectivity Assays
[0060] Antibody titers in guinea pig plasmas or monkey sera were determined by an indirect ELISA as described previously (Hevey et al., 1997, supra). Briefly, antigen consisting of purified, irradiated virus was coated directly onto PVC plates and serial dilutions of test serum were added to wells containing antigen. The presence of bound antibody was detected by use of the appropriate horseradish peroxidase conjugated anti-species antibody (HPO-goat-anti-guinea pig IgG H+L; HPO-goat-anti-monkey IgG H+L). Endpoint of reactivity was defined as the dilution at which OD405 was 0.2 as determined by extrapolation of a four parameter curve fit (SOFTmax�, Molecular Devices Corp. Sunnydale, Calif.) of background-subtracted mean OD versus dilution. Results shown in any table or figure are from a single assay to allow more valid comparison of endpoints. Plaque assays were performed on Vero E6 cells with a semi-solid overlay on serial dilutions of samples. Viral plaques were visualized by staining viable cells with neutral red 6-7 days postinfection. To measure plaque reduction neutralization, equal volumes of a virus stock (target plaque dose was 100 PFU) and serum diluted in cell culture medium were mixed and incubated at 37� C. for 1 h. The resulting sample was assayed by plaque assay on Vero E6 cells for more than a 50% reduction in PFU compared to control samples.
[0061] Clinical Laboratory Assays
[0062] For nonhuman primate studies, hematological results were obtained with a Coulter instrument, and differential counts were performed manually. Clinical chemistry results were obtained with a Piccolo� analyzer (Abaxis, Inc., Sunnydale, Calif.) using the diagnostic panel General Chemistry 12, which measures alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), amylase, aspartate aminotransferase (AST), calcium, cholesterol, creatinine, glucose, total bilirubin, total protein, and urea nitrogen.
[0063] Analysis of Protein Products Synthesized After Infection of Vero Cells with VEE Replicons That Expressed MBGV Proteins
[0064] Results of indirect immunofluorescence assay (IFA) analyses of Vero cells infected with different recombinant VEE replicons expressing MBGV proteins, are shown in FIG. 1. Expression of the indicated protein products was detected both with polyclonal guinea pig anti-MBGV and with monoclonal antibodies (MAbs) specific for the indicated MBGV proteins or, in the case of VP24 (for which no MAbs were available), with convalescent serum from a monkey that had survived infection with MBGV. There were distinct staining patterns for several of the expressed proteins. MBGV GP was observed as a plasma membrane fluorescence, while the GPΔTM provided a more diffuse cytoplasmic staining. These different staining patterns were not unexpected as GPΔTM, which lacks the hydrophobic transmembrane region of GP, is a secreted product. MBGV NP and VP35 formed discrete patterns in the cytoplasm of cells. MBGV VP40 demonstrated a more diffuse cytoplasmic staining pattern. MBGV VP30 was present in unique large globules staining in the cytoplasm of cells. MBGV VP24 staining was typically perinuclear. In summary, IFA served to assure that the appropriate antigen was expressed in a given preparation; it highlighted staining patterns, which demonstrated the localization of the expressed MBGV proteins in Vero cells; and it served as the basis for the assay whereby 10-fold dilutions of VRPs were quantitated for infectivity, as focus forming units (FFU).
[0065] Expression, antigenicity, and size determination of the MBGV proteins were confirmed by immunoprecipitation and gel electrophoresis. The results obtained from expression of MBGV GP, GPΔTM, NP, and VP40 in Vero cells are shown in FIG. 2. Products of the expected sizes were specifically immunoprecipitated from replicon-infected cell lysates. Glycosylation of MBGV GP more than doubles the predicted size of the peptide chain, and typically results in a heterogeneous array of posttranslationally modified products (Feldmann et al., 1991, Virology 182, 353-356; Feldman et al., 1994, Virology 199, 469-473), especially in GP from cell lysates, as shown in FIG. 2, lane 1. As expected and shown previously in the baculovirus system, GPΔTM was secreted, and thus present in the supernatant of replicon-infected cells (FIG. 2, Lane 3). Appropriately, both the cell-associated (lane 2) and secreted (lane 3) forms of GPΔTM appeared smaller than the largest forms of GP (lane 1). The secreted form of GPΔTM appeared larger and somewhat more homogeneous than the same molecule from cell lysates, as noted previously (Hevey et al., 1997, supra) (compare FIG. 2, Lanes 2 and 3). This difference likely reflects the more complete glycosylation of the secreted product compared to partially glycosylated forms of this protein expected to be present in the cell. In this gel, and with considerably less intensity in other preparations, an unidentified protein of approximately 46 KDa, which can be immunoprecipitated with GP-specific monoclonal antibodies (not shown), is evident in MBGV virions (FIG. 2, Lane 9). Although it remains to be confirmed, this product may be the glycosylated form of a putative 27 KDa cleavage product of GP, reported to be the result of a posttranslational, furin-mediated cleavage of GP (Volchkov et al, 1998, Proc. Natl. Acad. Sci. USA 95:5762-5767). Replicon-expressed MBGV NP (FIG. 2, Lanes 4-6) and VP40 (FIG. 2, Lanes 7-8) comigrated with the authentic proteins present in purified MBGV virions. In other experiments, the reactivity with polyclonal or MAbs and the authentic electrophoretic migrations of the remaining replicon-expressed MBGV proteins (VP30, VP35, and VP24) were similarly demonstrated (data not shown).
[0066] Protective Efficacy of VEE Replicons Expressing MBGV Proteins in Strain 13 Guinea Pigs
[0067] Groups of strain 13 guinea pigs were inoculated with packaged recombinant VEE replicons expressing individual MBGV proteins, and later challenged with 103.3 LD50 guinea pig-adapted MBGV subcutaneously. Results are shown in Table 1. MBGV GP protected guinea pigs from both death and viremia when administered as a three dose regimen. In addition, no reduction in efficacy or potency was observed when a two dose regimen was instituted, and significant efficacy was observed even when a single dose of 106 FFU of VRP expressing MBGV GP was used as an immunogen. The efficacy of either the two or three dose vaccine schedule was further demonstrated by the observation that no boost in postchallenge ELISA titers were observed. This result suggested minimal antigen exposure after challenge with MBGV, and thus robust or even sterile immunity in these animals. MBGV GPΔTM, which was previously shown to be protective as a vaccine when produced from insect cells, also protected guinea pigs from death and viremia when delivered in an VEE virus replicon. Again, there were no increases in postchallenge ELISA titers in the group of animals immunized with GPΔTM, thus no differences were discerned in the vaccine efficacy of membrane-bound versus soluble GP.
[0068] In the experiment shown, MBGV NP protected all vaccinated guinea pigs from both viremia and death, while MBGV VP35 vaccination resulted in five of six animals surviving, but four of the five survivors were viremic seven days postinfection. None of the other MBGV viral proteins cloned into VEE replicons evoked significant protection against a lethal challenge with MBGV. Thus, the proteins that showed the most promise as vaccine candidates in the guinea pig model were MBGV GP and NP. Cumulative results from this and additional experiments (not shown) in strain 13 guinea pigs inoculated three times with VRPs demonstrated complete survival with GP (18/18), and less complete protection with NP (16/18) and VP35 (13/18) as compared with controls (2/24).
[0069] Protection of Cynomolgus Monkeys Vaccinated with Recombinant VEE Replicons Expressing Either MBGV GP and/or NP
[0070] Encouraged by the success in vaccinating guinea pigs against MBGV, we evaluated the ability of these same VEE replicons to protect cynomolgus macaques from lethal MBGV infection. The monkeys received 10-fold higher doses of replicons, but on an identical schedule as tested in the guinea pigs. Four groups contained three monkeys each. One group received VRPs which expressed MBGV GP; a second group received VRPs which expressed MBGV NP; a third group received a mixture of MBGV GP and MBGV NP VRPs; and a fourth received VRPs which expressed a control antigen (influenza HA) irrelevant to MBGV immunity. Anti-MBGV ELISA antibody titers were monitored throughout the experiment.
[0071] All animals that received VEE replicons expressing MBGV GP, either alone or in combination with MBGV NP, survived challenge with 8000 PFU MBGV without any observed signs of illness (Table 2). Of the three animals vaccinated with MBGV NP, one died 8 days after challenge from MBGV disease. The other two NP recipients displayed signs of illness 7-9 days after challenge, but eventually recovered. One NP-inoculated survivor had a relatively mild disease (slightly reduced activity and responsiveness), while the other had severe disease which included obvious petechiae, loss of weight, reduced activity, and fever. All control animals succumbed, with clinical signs first noted on day 7 or 8, and deaths occurring on days 9 or 10 postchallenge.
[0072] The pre- and postchallenge ELISA antibody titers of the cynomolgus macaques are shown in FIG. 3. All animals inoculated with replicons that expressed MBGV proteins demonstrated prechallenge ELISA titers to purified MBGV antigen. Of the three GP-vaccinated animals that survived challenge, two demonstrated a modest boost in ELISA antibody titer (10-30 fold) when pre- and postchallenge samples were compared. The two surviving NP-inoculated macaques had larger boosts in ELISA antibody titers (100-300 fold) when pre- and postchallenge samples were compared. Two of three animals vaccinated with both GP and NP also demonstrated 100- to 300-fold rise in ELISA titers. These observations, in conjuction with the back titration of the MBGV challenge inoculum (8000 PFU), confirmed that all groups were unambiguously challenged, and that two monkeys had particularly robust immunity that apparently restricted virus replication below an immunogenic threshold.
[0073] A plaque reduction neutralization assay was performed on pre- and postchallenge serum samples. No neutralization activity was observed, at 1:20 or higher dilutions, in any sample. It should be noted that it is frequently difficult to demonstrate filovirus neutralizing antibody in vitro; however, antibodies may nonetheless be relevant in vivo (Hevey et al., 1997, Virology 239, 206-216), perhaps via mechanisms other than classical neutralization (Schmaljohn et al., 1982, supra).
[0074] The viremia levels in each of the monkeys at several time points after MBGV challenge are shown in FIG. 4. The data illustrate the profound differences between lethally infected control animals and healthy survivors. Most striking, none of the animals vaccinated with GP, either alone or in combination with NP, had infectious MBGV virus in their sera that was detectable by plaque assay. Animals vaccinated with a replicon expressing influenza HA were all viremic by day 3 postchallenge and demonstrated sharp rises in MBGV viremia levels which peaked at 7.5-8.0 Log10 PFU/ml on day 7 postinfection. Among monkeys vaccinated with NP, one died with viremias indistinguishable from controls. In contrast, the two NP-vaccinated monkeys that recovered had peak viremias that were diminished ≧1000 fold compared with controls. By day 10 postinfection, the NP-vaccinated monkey with the milder illness had no detectable viremia, while the more severely affected monkey still had �4.5 Log10 PFU/ml virus. By day 17 postinfection no viremia was detectable in either of the surviving NP vaccinated animals.
[0075] Additional Measures of Vaccine-Mediated Protection
[0076] Upon necropsy of the control and the unprotected NP-inoculated monkeys, MBGV titers in their livers were 9.2, 9.7, 9.4, and 9.6 Log10 PFU/gm. Virus was detected in all other organs examined as well, and although abundant, was at least 10-fold lower than in the liver. Not surprisingly, elevated liver enzymes were the most obvious abnormal feature in clinical chemistries. As shown in FIG. 5, unprotected monkeys had elevated AST levels by day 5 or 7 postinfection, and these were paralleled by similarly profound increases in ALT and ALP (not shown). Terminal samples were automatically rejected by the instrument as too lipemic or hemolyzed; however, in a previous set of control monkeys liver enzymes had continued to ascend dramatically (not shown). With regard to vaccine-mediated protection, it is instructive that the two NP-inoculated survivors exhibited marked but transient rises in their liver enzymes (FIG. 5), which is consistent with their viremias and signs of MBGV disease. Also, the more severely affected NP-inoculated survivor exhibited a transient rise in urea nitrogen and creatinine (not shown), coincident with recovery and viral clearance. This may have been due to virus-antibody complexes perturbing kidney function, or to direct viral damage to the organs. In contrast, the six monkeys vaccinated with GP exhibited either a minimal rise at one time point (i.e., the one GP animal shown in FIG. 5) or no significant increases in liver enzymes at any time evaluated. Other clinical chemistries and hematological findings remained normal in MBGV-inoculated macaques vaccinated previously with GP or GP+NP, in contrast with control monkeys that exhibited the expected profound end-stage abnormalities in both hematological and chemistry measurements (Johnson et al., 1995, Int. J. Exp. Pathol. 76, 227-236).
[0077] Discussion
[0078] To our knowledge, this is the first report of any filovirus vaccine shown to be completely efficacious in nonhuman primates. Before these observations, we were cautiously optimistic about the overall feasibility of an efficacious vaccine for MBGV, but were also concerned that proofs of filovirus vaccine concepts in guinea pigs may not necessarily forecast success in nonhuman primates and, by inference, in humans. Results presented here defined GP, possibly in combination with NP, as candidate antigens for a MBGV vaccine, and demonstrated that nearly complete immunity is achievable in nonhuman primates.
[0079] We chose an alphavirus replicon based on VEE virus to deliver the antigens of interest. This method of vaccination has several advantages (Pushko et al., 1997, Virology 239, 389-401), including the ability to produce large quantities of antigen in situ, so that native processing of the antigens might evoke a broad array of immune responses. In addition, all transcription of RNA occurs in the cytoplasm of cells, which avoids RNA splicing problems sometimes observed when proteins of RNA viruses are expressed from the nucleus. Moreover, VEE replicons have proven stable after packaging into VRPs. In addition to robust antibody induction, alphavirus replicons have been demonstrated to elicit cytotoxic T lymphocytes in mice (Caley et al., 1997, J. Virol. 71, 3031-3038; Zhou et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92, 3009-3013). The success reported here using VEE replicons to vaccinate monkeys against lethal MBGV challenge justifies a more detailed analysis of the potential of these vectors for use as human vaccines. These analyses may include such factors as the relevance of host-vector interactions that may affect vaccine potency, overall safety of the vector, and the duration and minimal requirements for immunity to MBGV disease induced by this vector.
[0080] Two viral antigens demonstrated unambiguous potential as protective antigens in the guinea pig model: MBGV GP and MBGV NP. Another viral antigen, VP35, provided significant protection from death; however, most (5/6) animals vaccinated with VP35 exhibited viremias 7 days after infection. Consequently, VP35 was not considered a candidate for the initial examination of vaccine efficacy in nonhuman primates. While none of the other viral antigens showed significant promise as protective antigens in the guinea pig model, some were only weakly immunogenic, at least when delivered as VRPs. Thus, we have not formally excluded the possibility that such antigens may prove protective under different circumstances, or in species other than guinea pigs.
[0081] As a more definitive test of efficacy, the two most promising guinea pig protective antigens from MBGV were used to inoculate nonhuman primates either alone or in combination. Using recombinant VEE replicons, MBGV GP was clearly shown to be protective. The observation that none of the animals developed overt illness or viremia was conclusive proof that this vaccine approach had protected animals from a substantial challenge dose of MBGV. However, there were some significant differences observed between guinea pigs and cynomolgus macaques. Most notable was the observation that two-thirds of the GP-vaccinated monkeys demonstrated rises in ELISA antibody titers following MBGV challenge, whereas there was apparently sterile immunity (i.e. no further increases in antibody titers) to viral challenge in guinea pigs given a 10-fold lower dose of the same vaccine. This may be attributable to the overall higher prechallenge ELISA antibody titers observed in guinea pigs when compared to those observed in the monkeys (Table 1 vs. FIG. 3).
[0082] The second antigen examined, MBGV NP, was less effective at protecting nonhuman primates compared to guinea pigs. All the monkeys inoculated with NP displayed signs of illness, with one animal dying in the same time frame as control animals. All animals were viremic, and viremia levels were predictive of outcome. As expected, the two animals that survived illness had large boosts in their ELISA antibody titers against MBGV when pre- and postchallenge sera were examined. Though not statistically significant in a group of only three animals, MBGV NP was apparently able to provide a measure of protection from death, but not from disease in two monkeys. We surmise that the immune response to NP was sufficient to suppress replication of MBGV until augmented by additional host immune responses.
[0083] The monkeys that were vaccinated with both MBGV GP and NP demonstrated the same degree of protection as the animals vaccinated with GP alone. No viremias were observed at any time point, and two of three animals demonstrated postchallenge increases in ELISA antibody titers to MBGV. These results demonstrated that the NP replicon, equivocal by itself as a macaque vaccine, did not interfere with a GP-based vaccine when protective efficacy was used as a measurement.
[0084] For these studies, in the interest of expedient vaccine development, protection from viral disease was prioritized over the detailed study of immune mechanisms in two relatively difficult animal species for immunological studies, guinea pigs and cynomolgus macaques. It was already clear from studies done in guinea pigs that ELISA antibody titers to MBGV were not wholly predictive of clinical outcome, but rather one measure of immunogenicity of the vaccine candidate. However, it was also known that administration of polyclonal antisera or a neutralizing MAb could protect some guinea pigs from lethal challenge, indicating that antibodies can play a role in the protective response to MBGV (Hevey et al., 1997, supra). As for immunity to virtually all viruses, T cell responses to MBGV are almost certainly important in their immunoregulatory and effector functions. Indeed, we observed protection in both guinea pigs (NP and VP35) and nonhuman primates (NP) with antigens for which the most logical protective mechanisms involve cellular immunity. However, it also proved emphatically true in the most susceptible animals�nonhuman primates�that protective immunity was elicited by an antigen (GP) that theoretically favored a redundant protective response of both T cells and antibodies.
Referenced by
Legal Events
Original Image


text:
Presho couple honored for decades of work with foster kids
PRESHO -- Bob and Jan Fuller, of Presho, have been honored with a 2012 Angels in Adoption award for their commitment to foster children.
The Fullers were nominated by Rep. Kristi Noem, R-S.D.
They have fostered more than 200 infants over the past 40 years. They take care of the children until they can be returned to their biological parents or placed with an adoptive family.
Get the full story
Subscribe or Log In
Are you a newspaper subscriber but you don't have a Digital Access account yet? Activate your account.
You will need your subscription account number and phone number. Not sure if you have an account? Email us or call (605) 996-5514 and we can help you.

subset: commoncrawl


text:
THR film critic Stephen Dalton argues that Christopher Nolan's new space epic isn't full of wonder — it's full of itselfRead more
The Batman-centric studio tour will be open for a limited run this summer featuring Batmobiles, costumes and props from all seven films in the same place for the first time ever.Read more
The toy company has already announced a line of "Teenage Mutant Ninja Turtles" toys and new sets for "The Hobbit."Read more
Joss Whedon's superhero hit sold 34 times as many copies as the No. 2 title, "Batman: The Dark Knight Returns — Part 1."Read more
Warner Premiere is set to release an adaptation of Frank Miller's iconic 1980s miniseries featuring Peter Weller ("Robocop") as the voice of the Caped Crusader.Read more
What's hot in the world of fanboy entertainment,
from blockbuster films to the comic books that inspire them.
Brought to you by Borys Kit.
Breaking TV show news, Nielsen ratings & analysis
Entertainment law news and analysis by Matthew Belloni and Eriq Gardner
Frontline reports from the awards circuit-breaking news, instant analysis and fearless predictions.
Behind the Screen explores the impact of technology on movies and TV shows, specifically content producers, cinematographers, editors, VFX shops and artists, sound mixers and editors, technical (including R&D) roles and the post-production community. This includes products from companies like Red, Canon, Dolby and Avid to new hires in key below-the-line positions on movies or at below the line post/VFX shops
TV show reviews, recaps, and analysis by Tim Goodman, Chief Television Critic
What music people are talking about
View gallery
The Hollywood Reporter
©2015 The Hollywood Reporter.All rights reserved.
Terms of Use |
Privacy Policy
Our affiliate publications


text:
Gophers Select 2013-14 Award Winners
March 16, 2014
Junior Rachel Banham was named the recipient of Minnesota's Most Valuable Player award, highlighting the Gopher women's basketball program's annual team banquet, which took place in the DQ Club Room at TCF Bank Stadium Sunday night.
Banham became the first Gopher since 1993 to lead the Big Ten in scoring, and her 23.3 points-per- game average was the highest in the Big Ten since 2002. Additionally, Banham led the Big Ten with 20 games scoring 20 or more points and five games scoring 30 or more points.
More Headlines
3/26/2015Zahui B. Named Wade Trophy Finalist
3/25/2015Five Gophers Named Academic All-B1G
3/23/2015Gopher Banquet Set for March 31
3/18/2015BLOG: We're Talking About Practice
03/17/2015WBB Video Features: Zahui B.
03/16/2015Gophers Earn Berth in NCAA Tournament
03/13/2015Zahui B. Earns espnW All-America Status
03/11/2015WBB Video Features: On The Road
03/09/2015Zahui B. on Wooden Award National Ballot


text:
News from WTOP
News from the AP
Mike Causey
Shows & Panels
- Agency of the Month
- Business of Government Hour
- The CFO Agenda: Delivering value from financial transparency and audit efforts in the public and private sector
- Cloud-Driven Data Insights in Government
- CXO Surveys
- Disaster Resilience for America
- Federal News Countdown
- Government Perspectives on Mobility and the Cloud
- Reducing Risk in the Cloud
- Reimagining the Next Generation of Government
Shows & Panels
- AFCEA Answers
- American Readiness: Renewable Power and Efficiency Technologies
- Ask the CIO
- The Business Case for Cloud Computing in Government
- Cloud-Driven Data Insights in Government
- Delivering the Digital Government Mission
- Federal Executive Forum
- Federal News Radio's National Cyber Security Awareness Month Special Panel Discussion
- Federal Tech Talk
- The Future of Government Data Centers
- Government Perspectives on Mobility and the Cloud
- Industrialized, Interoperable and Insight-driven Federal Health Panel
- Innovation and Tech Superiority through Acquisition Reform
- Mitigating Insider Threats in Virtual & Cloud Environments
- Moving Agency Applications to the Cloud with PaaS
- Reducing Risk in the Cloud
- Security in the Age of Targeted Attacks
- Air Traffic Management Transformation Report
- The Business of Cloud
- Cloud First Report
- Disaster Resilience for America
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- The Intersection: Where Technology Meets Transformation
- Modern Mission Critical Series
- National Cybersecurity Awareness Month
- The New IP for Federal IT
- The Social Platform Solution for the Department of Veterans Affairs
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
- Cloud-Driven Data Insights in Government
- Disaster Resilience for America
- F-35 Lightning II Program
- Government Perspectives on Mobility and the Cloud
- On DoD
- Pentagon Solutions
- Reducing Risk in the Cloud
- Reimagining the Next Generation of Government
- Transforming Business Operations at the Defense Department
Monday - Friday, 4-7 p.m.
In Depth with Francis Rose features daily interviews with top government executives and contractors. Listen live from 4 to 7 p.m. or download his archived interviews below.
Monday federal headlines - February 23, 2015
The Federal Headlines is a daily compilation of the stories you hear discussed on Federal News Radio each day. It is designed to give FederalNewsRadio.com readers more information about the stories heard on the radio. In today's news, the government sends wrong tax information to 800,000 HealthCare.gov customers, key federal cybersecurity initiatives would be an early casualty of a Homeland Security Department funding lapse and a female soldier makes launcher chief history.
Federal News Countdown: Obama budget, 'Wild West' Internet
Jim Carafano, director of the Kathryn and Shelby Cullom Davis Institute for International Studies at the Heritage Foundation, and Ron Sanders, vice president and fellow at Booz Allen Hamilton, count down the week's top federal headlines with Francis Rose.
Kevin Collins, Spokesman, Office of Inspector General, EPA
Potential fraud at the Environmental Protection Agency is attracting congressional attention. Members asked EPA's Office of Inspector General to investigate a specific case involving a senior policy Adviser at the agency named John Beale. Kevin Collins is spokesman for EPA OIG and contributed to its report. On In Depth with Francis Rose, he explained the details of the case and why Congress is paying attention.
Jared Serbu, DoD Reporter, Federal News Radio
The Pentagon has been warning for years that the decade-long budget caps Congress set in place four years ago won't work -- at least if DoD hopes to execute the defense strategy that's on the books right now. With sequestration set to return this year, officials say they'll try to make things a bit less abstract. The Pentagon publishes a report that details exactly what would happen to individual bases and weapons systems with a $30 billion cut. Federal News Radio DoD Reporter Jared Serbu writes about DoD's sequestration messaging strategy as part of this week's edition of Inside the Reporter's Notebook.
Tammy Flanagan, National Institute of Transition Planning
You have two basic retirement-planning options with the Thrift Savings Plan. You can leave your money in, or take it out. Tammy Flanagan is Senior Benefits Director for the National Institute of Transition Planning. On In Depth with Francis Rose, she said there are pros and cons for both, but you need to think carefully before you decide what to do.
From scandal's aftermath to 18F, Tangherlini reflects on tenure at GSA
When Dan Tangherlini took over as the General Services Administration administrator in 2012, it was embroiled in the aftermath of the conference scandal. Stepping down after three years later, he reflects on how the agency has transformed itself.
Jason Miller, Executive Editor, Federal News Radio
The General Services Administration (GSA) and the National Oceanic and Atmospheric Administration (NOAA) have one thing in common. They're both preparing several new opportunities for contractors. By March, contractors can expect a series of draft and final requests for proposals for some of the largest IT service contracts in the government. Federal News Radio's executive editor Jason Miller joined Tom Temin on the Federal Drive with details on the next wave of big RFPs.
Friday federal headlines - February 20, 2015
The Federal Headlines is a daily compilation of the stories you hear discussed on Federal News Radio each day. It is designed to give FederalNewsRadio.com readers more information about the stories heard on the radio. In today's news, a former Army captain is sentenced to five years in prison for wire and mail fraud, a new research center will help local governments increase their resilience to natural disasters and the operation to retake Iraq's second largest city from Islamic State militants will likely begin in April or May.
Roger Waldron, President, Coalition for Government Procurement
The horror story of the $600 toilet seat is many years behind us. But the 21st Century equivalent may be the $29 stapler that Richard Ginman used as an example for why the Defense Department would audit General Services Administration schedules. Roger Waldron is president of the Coalition for Government Procurement. On In Depth with Francis Rose, he said that story of the stapler got him motivated to do some research, and see if he could find that stapler.
Zina Merritt, Director of Defense Capabilities, GAO
The Pentagon has decades-old management problems it needs to scrub if it wants to get off the High-Risk List at the Government Accountability Office. But the department has changed a lot since GAO first added its business transformation plan to the list in 2005. Zina Merritt is director of defense capabilities and management issues at GAO. On In Depth with Francis Rose, she explained how close DoD is to getting its plan off the High-Risk list.
Maj. Gen. Steve Smith, Former U.S. Army, Pat Park, Metalogix
Edward Snowden and Bradley Manning personify the concept of the insider threat. Defending against that threat is now one of the highest priorities for the military and intelligence communities. Retired Army Maj. Gen. Steven Smith is former chief information security officer for the Army. He's now Security Technology Adviser to Metalogix. Pat Park is vice president for public sector at Metalogix. On In Depth with Francis Rose, they explained how agencies can tackle the different types of insider threats.
Thursday federal headlines - February 19, 2015
The Federal Headlines is a daily compilation of the stories you hear discussed on Federal News Radio each day. It is designed to give FederalNewsRadio.com readers more information about the stories heard on the radio. In today's news,
Jared Serbu, DoD Reporter, Federal News Radio
By one measure, the Defense Department's health care bill is triple what it was 15 years ago. By another, medical costs make up 10 percent of the military's budget, compared to 6 percent in 2000. A new report from the Center for a New American Security says the department has to get health spending under control, and offers two main prescriptions. Peter Levin is an adjunct fellow at the center, and also a former chief technology officer at the Department of Veterans Affairs. In an interview with Federal News Radio's Jared Serbu, he says it's true that the nation's overall health care costs have been rising, but DoD seems to be last in line to address the problem.
Bill Phillips, principal, KPMG
The new Secretary of Defense, Ashton Carter, will have some new input on transforming business operations at the department. The Defense Business Board has recommendations for Carter and his colleagues at the top of the Pentagon for improving the department's business operations. Bill Phillips is principal in charge of the federal advisory unit at KPMG. He's also chair of the Defense Business Board task force, and on In Depth with Francis Rose, he shared the recommendations.
Dan Tangherlini, administrator, General Services Administration
Dan Tangherlini calls back office functions in government "the boiler room." And he has positioned the General Services Administration to be the leader in providing services that stoke the boiler for agencies across government. Friday is his last day as GSA Administrator. On In Depth with Francis Rose, he discussed the federal real estate portfolio, GSA's establishment of 18F as one of the early leaders in digital services in government, and much more.
Bob Hale, Booz Allen Hamilton, and Dov Zakheim, CSIS
Sequestration is still the law of the land, and the spending cap that the government has to work under is about $498 billion for the defense budget. But more and more members of Congress say that's not enough for the Pentagon. Dov Zakheim is senior adviser at the Center for Strategic and International Studies. Bob Hale is a fellow at Booz Allen Hamilton. Both have served as Undersecretary of Defense Comptroller. On In Depth with Francis Rose, they talked about the possibilities for an agreement on the defense budget.
Jason Miller, Executive Editor, Federal News Radio
If you've never heard of the Invoice Processing Platform, you're probably not alone. It's a system for handling electronic transactions with vendors. And now the Office of Management and Budget is developing new guidance that strongly encourages agencies to use it and it alone. At the moment, your chief financial officer is commenting on the draft guidance. It's all part of OMB's more aggressive push to shared services in 2015. Executive Editor Jason Miller joined the Federal Drive with Tom Temin to discuss what he's found out about the draft guidance, and where OMB is heading with shared services.
Wednesday federal headlines - February 18, 2015
The Federal Headlines is a daily compilation of the stories you hear discussed on Federal News Radio each day. It is designed to give FederalNewsRadio.com readers more information about the stories heard on the radio. In today's news,
Emily Kopp, Reporter, Federal News Radio
The 7,000 or so people that make up the Senior Executive Service are the focus of Federal News Radio's latest special report. Emily Kopp presents the special report called "Fixing the SES." Emily tells In Depth with Francis Rose, there's a possible trend in the talk about fixing the SES.
John Reeder, Deputy Chief of Staff, and Noha Gaber, EPA
Online dating has come to the EPA. It's not a romantic thing, but the concept is similar. The agency's new skills marketplace lets employees apply for projects throughout the agency. If selected, they get to do the new work, develop their skills and meet new colleagues all without leaving their day jobs. Now other agencies are paying attention. Federal News Radio Reporter Emily Kopp spoke with John Reeder, the EPA deputy chief of staff, and Noha Gaber, the acting director of internal communications. John explains why the EPA launched the marketplace.


text:
How Far Can Superman Cast?
- By: Buzz Bryson
- and Paul Guernsey
Plus, what you can learn from wiggling a fly rod
Tying the Callibaetis Quill Dun
- By: A. K. Best
A must-have pattern even on streams
Sulphur Quill Dun
- By: A. K. Best
A springtime standby
Tiny Dubbed BWO's
- By: A. K. Best
Just in time for the first spring hatches...
Trico Quill Duns
- By: A. K. Best
Early morning anglers should have a dozen of these in their fly boxes
Biot Eastern March Brown
- By: A. K. Best
A variation on the Western version
Driftboat Fishing: The Ins And Outs
- By: Buzz Bryson
Plus, are guides allowed to yell?
Black Midge Emerger
- By: A. K. Best
I can't count the number of times I've hit a hatch of black midges on a stream, pond or lake. They seem to thrive everywhere and trout seem to thrive on them as well. They can range in size from 14 to tiny 22's. Years ago I tied both emergers with trailing shucks and the winged adults. Since then I've
A.K.'s Hopper
- By: A. K. Best
This hopper hybrid is both durable and easy to tie
Yikes, Trikes!
- By: A. K. Best


text:
|Great flick from Mario for that goal.
#9673142, By Jono62 What is the Confederations Cup?
Jono62 14,638 posts
Seen 4 hours ago
Registered 7 years ago
Bloodborne guide: bosses, areas and secrets Our essential guide to Miyazaki's latest dark adventure.
Pillars of Eternity walkthrough Our guide to the long-awaited RPG from Obsidian.
Loading... hold tight!
|Great flick from Mario for that goal.


text:
Beyonce's Deja Vu
Beyonce's Deja Vu
Expect to see a lot more of Beyonce this fall. Along with her new album in September, she has landed a a deal with the Style Network. Here's more:
The programming and marketing partnership between Style Network, Beyoncé and her mother and partner, Tina Knowles, will feature programming throughout the third and fourth quarter of 2006 about Beyoncé's clothing line, House of Deréon. This will include Uncut: House Of Deréon Featuring Beyoncé & Tina Knowles, a one-hour behind the scenes look at the singer as she prepares to release her new CD and launch her clothing line; House Of Deréon Runway Special, a 30-minute special with fashion show footage; and Everyday Runway with Beyoncé and Tina Knowles.
In the meantime, you can check out the video for Deja Vu featuring her man, Jay-Z.
Lots more pics of Jay-Z and B so read more
Jay Z
- Find out what Taylor Swift said about her doppelgänger — Us Weekly
- Justin Guarini, is that really you?! — HuffPost Celebrity
- Here's what Outlander star Sam Heughan is like in person — Lainey Gossip
- Julia Roberts has a major problem with Nicole Kidman — Dlisted
- Lena Dunham's new written piece is causing a stir — ET
- Inside Kate Mara and Ellen Page's day at Disneyland — JustJared
- Kate Upton is showing major cleavage for Guess — Hollywood Tuna
- Which Britney Spears video turns 15 today? — Pink Is the New Blog
- Rita Ora's airport attire makes quite the statement — The Superficial
- Land a copy of Madonna's latest album — popbytes


text:
Egypt: Man who tore Bible to go on trial for blasphemy
Egypt: Man who tore Bible to go on trial for blasphemy by Katherine Weber, The Christian PostPosted: Friday, September 28, 2012, 9:13 (BST) In a rare exercise of its anti-blasph
By: ElegantDecline | Comments: 50 | Views: 1364 | Votes: 1 | Shared: 0
Location: Egypt | Leaked: Sep-30-2012 in World News, Politics, Other Middle East
FAKE SYRIAN ARMY SHOW- Fake Protest, Fake UN Observers, Fake Gunfire- April 23rd, 2012
This is how to fake a protest, do your own gunfire, direct a shot at a mosque minaret for the camera, and call for the UN observers who were not even there at all! Please, someone send the "Free Syria
By: C-A-T-000p | Comments: 17 | Views: 4279 | Votes: 3 | Shared: 0
Location: Syria | Leaked: Apr-27-2012 in Other Middle East
Father Cries Over His Dead Son's Body- Taftanaz, Syria
The only way forward for Syria is the Annan peace plan, not the US administration's method of backing violence of one side against the other. Or this will be the result, as the foreign backers stir up
By: C-A-T-000p | Comments: 7 | Views: 5375 | Votes: 0 | Shared: 1
Location: Syria | Leaked: Apr-5-2012 in Other Middle East
Armed Factions Terrorise Streets Of Aleppo In Presence Of Children
Never bring children to a fire fight. And when they die because you did bring them, don't film them with holes in their heads and talk about an oppressive regime! Blame yourself for taking up arms and
By: C-A-T-000p | Comments: 22 | Views: 3928 | Votes: 0 | Shared: 0
Location: Syria | Leaked: Mar-25-2012 in Other Middle East
FSA Terrorists Attack Civilians And Children In Damascus Suburb
Homegrown Syrian terrorists attack civilians in a quiet Damascus suburb, leaving carnage, death and destruction before they are all killed or captured by the army in Maza district. The video shows the
By: C-A-T-000p | Comments: 10 | Views: 6963 | Votes: 1 | Shared: 117
Location: Syria | Leaked: Mar-21-2012 in Other Middle East
Biblical Pornography "Yet she multiplied her whoredoms, in calling to remembrance the days of her youth, wherein she had played the harlot in the land of Egypt. For she doted upon their paramours, w
By: mujahideenjihad | Comments: 21 | Views: 10171 | Votes: 0 | Shared: 0
Location: Afghanistan | Leaked: Dec-25-2011 in Religion
Man with 'Israel' tattoo charged with attempting to assassinate United States President
Man with 'Israel' tattoo charged with attempting to assassinate Obama Jewish Telegraphic Agancy November 17, 2011
By: ElegantDecline | Comments: 63 | Views: 1425 | Votes: 0 | Shared: 0
Location: Washington, District of Columbia, United States | Leaked: Nov-22-2011 in Regional News
Model of a very modern rioter: Aspiring glamour girl, 22, jailed for six months
Model of a very modern rioter: Aspiring glamour girl, 22, jailed for six months after getting caught looting Croydon Argos store As magistrates and police work tirelessly to track down and punish
By: 24038462 | Comments: 58 | Views: 8850 | Votes: 1 | Shared: 0
Location: United Kingdom (UK/GB) | Leaked: Aug-12-2011 in World News, Other News, Politics
'1000 Christians' Slaughtered by Ivory Coast Rebels...
At least 1,000 Christians were slaughtered this week at the Salesian Saint Teresa of the Child Jesus mission in Duekoue, Ivory Coast by Muslim troops loyal to Alassane Ouattara. Catholic priests are a
By: Muhammad_ibn_Abdullah | Comments: 85 | Views: 8221 | Votes: 1 | Shared: 0
Leaked: Apr-5-2011 in News
Boy "allegedly" Urinates on Quran, Two People Killed in 'Revenge'...
Sokoto — Youths in Iraqi area of Sokoto metropolis yesterday sparked a violent protest over an alleged defilement on the Holy Qur'an. The incident, according to eyewitnesses, came when a boy (nam
By: Muhammad_ibn_Abdullah | Comments: 75 | Views: 7246 | Votes: 0 | Shared: 0
Leaked: Apr-5-2011 in Iraq, Middle East
Nigel Farage (UKIP) Admits to Taking £2,000,000 in Expenses
May 19, 2009 UKIP party leader Nigel Farage has dealt his party a death blow by "cheerfully" announcing that he has taken "more than £2 million in expenses" from his time in the European p
By: 24038462 | Comments: 5 | Views: 11245 | Votes: 0 | Shared: 0
Location: Stafford, Staffordshire, United Kingdom (UK/GB) | Leaked: May-19-2009 in News, LiveLeaks, Other
Tories Commit to Islamification of Britain
May 19, 2009 The Conservative Party has openly committed itself to the further Islamification of Britain with the launch of its "Local Muslim Forum" programme which is designed to entrench foll
By: 24038462 | Comments: 8 | Views: 7777 | Votes: 0 | Shared: 0
Location: Stafford, Staffordshire, United Kingdom (UK/GB) | Leaked: May-19-2009 in News
Search results for IncitementSort by:
Item Menu


text:
Ayers Lake Family Campground
Barrington, New Hampshire
Phone: (603) 332-5940
Visit Campground Website
Sites: 51
Recent Rate: $40 7/2010
Latitude: 43.238875
Longitude: -71.054693
These reviews are the opinion of an RVParkReviews' member and not the views of RVParkReviews.com
Date of Stay: July, 2010 - $40.00
Nice lake with some great spots around the lake. Very quiet, nice owners. Some of the seasonal units are pretty run down but the people make up for it. Campground also has a group of very old and really cool cottages on the lake. They look fun. We had a good time. We camped at Ayers Lake Family Campground in a Travel Trailer.Undo
Date of Stay: May, 2007 - $42.00
This campground is great! It is a old New England farm on a lake. The fishing is great. The site we stay on (4 years in a row) is right on the water. The door of our camper is thirty feet from the lake shore. The owners will bend over backwards to make your stay a good one. We camped at Ayers Lake Family Campground in a Travel Trailer.Undo
10 Ratings
Strafford, New Hampshire
23 Ratings
West Ossipee, New Hampshire
6 Ratings
York Beach, Maine
Pre-Register below to access free and enhanced features coming in the near future.
Access to marketing tools, ability respond to reviews and monitor performance as well as expanded listings.
Essential Marketing resources, page insights, daily reports, setup and manage notifications of newly posted reviews.
Expand your listing, Add photos and videos, update business details and more.
More Information about our Campground Owner Management and its enhancements are coming very soon. Features subject to change.


text:
Winter Trainer Sessions
Tired of sitting on your trainer alone? Well not anymore!
Come into the store every Monday, Wednesday, Friday at 6 p.m. and Sundays at 3 p.m. for a group ride.
BYOT (Bring your own trainer)
However, trainers available, but very limited, call ahead to reserve.
Classes are free and open!
See you soon!
Winter Clinic Series
Clinics are free and begin at 6 p.m. and last until about 7 p.m.
Jan.1st- New Years Day Polar Bear ride!
Location TBD, call store for details.
Jan. 14th- Fixing a Flat
Jan.21st-Bike Maintenance cancelled
Jan. 28th- Emergency Repairs
Feb. 4th- Adjusting your Derailleurs
Feb. 11th- Truing Wheels
Feb. 18th- Adjusting Hubs, Headsets, Bottom Bracket
Feb. 25th- Bleeding Hydrolic Brakes
March 4th- Ladies Night! (Details TBD)
March 11th- Nutrition
March 18th- Fitness and Training
March 25th- 1st "Wednesday Night Ride" of the 2015 Season! Take-off 5:30 p.m. SHARP. "Wednesday Night Ride" will last until mid-October.
-Further events, rides, services, etc. TBD


text:
My Cart
Store Locator
VIP Membership Terms: Normally $24.99 per year, but your Web Exclusive deal means you enjoy 3 months of VIP Family Benefits for $1.99. Check out your savings and benefits below.
Cancellation: Rest assured you can cancel your new membership at any time during the year at a pro-rated rate, simply call your VIP Hotline at 800.543.7309 or click here to submit your cancellation request. Benefits and prices are subject to change.
Want more info? Click here and read 'til your heart's content or call your VIP Hotline at 800.543.7309
Get the Latest, Sign Up Now!
Women's R-Gear
Zip To It Jacket
Zip To It Striped Jacket
Forever Denim Jacket
Women's Nike
Gym Vintage Full Zip Hoodie
Women's Under Armour
Big Logo Applique Hoody
Aeroloft Hybrid Jacket
Element Shield Full Zip Jacket
Women's Brooks
Nightlife Essential Vest III
Power Puff Jacket
Weather The Storm Jacket
Taken By Storm Rain Jacket
In Your Element Rain Jacket
Blown Away Jacket
Dry-Run Soft Shell Jacket
Night Watch Jacket
Best Defense GORE-TEX Jacket
Lace To Go Jacket
Peak Performance Jacket
Surge Warm-Up Jacket
Adapt Jacket
Shield Flash Jacket
UA Qualifier Woven Jacket
Nightlife Essential Jacket III
Back to top
ENJOY YOUR BIGGEST BENEFITS EVERY DAY Get FREE Shipping every day • Your WARP SPEED PROMISE • Ultimate Test Run 90-Day Wear 'em & Love 'em Guarantee • tons more perks! JOIN NOW!! �
Become a Fan & Follow Us.


text:
Next day service available at no extra cost for emergency requests
32529 Okaloosa Trail
Sorrento, FL 32776
Billboard - The latest coupons and news on this business!
Call now and get a discount on prepaid land surveys!
DSW Surveying & Mapping, PLC is locally owned and the most trusted Florida Land Surveyor around with 30 years experience. We provide all aspects of construction layout; specializing in residential and commercial land surveys in Florida; Sorrento, Eustis, Orange County, Osceola County, Lake County, Polk County, Sumter County, Volusia County, Mount Dora, Orlando, Kissimmee, Leesburg, Tavares; Boundary, Topographic, Elevation Certs, ALTA/ACSM. We service all Florida counties.
* Fully licensed & insured * Will meet or beat competitors pricing
* Customer service is our middle name * Next day service available at no extra cost for emergency requests * Cash/Check/Amex/MC/Visa/Discover/PayPal; easy order via fax, web or email
Category: Surveyors
trustworthy, excellent service, and fast by Happy Customer - 05/10/2012
I needed a rush land survey and they were very accommodating, very professional and came through in a pinch. I will use them again if I ever need a land survey.
DexKnows Mobile profile for DSW Surveying & Mapping, PLC in Sorrento, FL


text:
Recycled Plastic Luggage Tag
Roll over image to zoom in
Live green no matter where you go! Hand-crafted from recycled plastic bags, the resulting tough fabric makes this tag great for everyday use and for withstanding whatever the elements bring -- just like the resilient women who make them. Made from plastic bags gathered from trash heaps in east New Delhi by Conserve India, a non-governmental organization (NGO) on the cutting edge of both environmental issues and women's fair trade. How's that for happy travels?
- Choose Rainbow, Bobby Black, Classic Stripe or Ladybug
- 5" H x 3" W (12.7 x 7.6 cm) with a 2" L (5.1 cm) rubber strap
- Attaches to luggage with a lobster-style clasp
- Opening for contact information card
- Handmade in and fairly traded from India
Shop Green!
Created to help women worldwide gain economic security for themselves and their families by earning fair wages for their handiwork, Global Girlfriend sources women-made, fair-trade imported, eco-friendly products. By supporting long-term partnerships with the artisans, it fosters equal employment opportunities, healthy and safe working conditions, technical assistance, and development strategies to help reduce poverty, one community at a time. Become a "Global Girlfriend" and help build a brighter future for girlfriends around the globe!
For bulk pricing on these and other items, please contact our Customer Service department at firstname.lastname@example.com.
People buying this item also bought:
From $1.00
From $5.00
From $16.99
On Sale!
From $1.00
Tie Dye Spirit Crocheted Long Sleeve Top
From $24.00
Special Value!
Recycled Magazine Dragonfly Ornament
From $5.95
From $4.00
Special Value!
One of our favorites!
From $19.99
On Sale!
One of our favorites!
Start Your Day with Faith Car Charm
From $12.95
One of our favorites!
"I Am Complete" Swarovski Crystal Paw Ring
From $16.99
On Sale!
From $26.95
One of our favorites!
From $42.95
Buy a Coat, Give a Coat!
Hebrews 13:5 Corded Scroll Bracelet
From $21.99
On Sale!
Artisan: Conserve India
Over a decade ago, Anita and Shalabh Ahuja left their comfortable life and careers to launch an environmentally savvy idea that helps reduce trash in the city while helping poor women find opportunity. With their life savings and extreme dedication, the couple launched an amazing concept that started as a 'green' project but quickly developed into much more. Conserve India creates purses and other products from recycled plastic bags gathered from trash heaps and is a source of hope for low-caste women who are desperate and homeless, giving them the opportunity to grow through education and employment opportunity. Conserve now employs and empowers over 300 low-caste women who were without employment opportunities before the non-profit group was established.
Conserve has developed an impressive system of production for their products. Women gather shopping bags from the dumps of New Delhi and bring them back to the shop where the plastic is thoroughly cleaned, dried, and then fused together by a process developed by Shalabh. The fusion process creates a durable fabric that is sewn into an array of accessories ranging from bags to day planners.
The women of Conserve have refused to leave their lives to fate. In India's extreme poverty, many are forced to sift through the rubble to find shelter or food to survive. Conserve has created some hope amongst that urban waste; because of Conserve, many of these women now have a greater potential for a better living, an education and a new life.
More items from Conserve India: View all ▸
One of our favorites!
Popular Now:
Midnight Dragonfly Soup Spoon Set
From $10.95
One of our favorites!
Leave the Rest to God Heart Bracelet
From $12.99
On Sale!
From $0.90
On Sale!
Cosmic Butterfly Sleeveless Tunic
From $20.00
Special Value!
The Food Recovery Network T-Shirt
From $14.95
More colors available...
More colors available...
Liberate Girls from Indentured Servitude
From $10.00
Greg's Pink Ribbon Crocheted Shoes
From $12.71
On Sale!
From $1.00
From $4.00
Special Value!
Contribute To Children's Literacy
From $1.00
Just Believe Dragonfly Fold-up Tote Bag
From $8.00
Special Value!
From $5.00
Syrian Refugee Families - Help Now
From $15.00
From $5.99
On Sale!


text:
Cocktail & Mocktail Recipes
From skinny sips to boozy martini recipes, we've got all the refreshing drinks you're looking for.
It's not fall unless you've had your pumpkin spice latte. And for an extra kick in your... READ MORE
Put a twist on your cocktail favorite with this fruity and tart recipe. READ MORE
With a dash of pineapple juice and spicy peppers, this ain't your grandma's margarita... READ MORE
We've found the perfect drink to toast the New Year with! This budget-friendly champagne... READ MORE
Get your shot glass molds out and make your very own delicious holiday wreaths! This... READ MORE
The traditional bloody mary gets a spicy makeover with this hot-hot-hot recipe. READ MORE


text:
Genital Rubbing And Dna Pcr Testing
Here's a taste of what TheBody.com has to offer on this topic:
Get the Facts
Herpes Simplex (Cold Sores and Genital Herpes)...However, it can become active again with no warning. Herpes can be active without symptoms or visible signs. Herpes simplex virus 1 (HSV1) is the common cause of cold sores (oral herpes) around the mouth. HSV2 normally causes genital herpes. However, through sexual activity, HSV1 can cause infections in the genital area, and HSV2 can infect the mouth area. HSV is a very common disease. Approximately 45 million people in the US have HSV...
Ask the Experts
please answer and how do i donateif liver results are normal on standard lab test is fear of hepatitis c or b gone. and can testing at 6 months rule out hiv even if you have hepatitis c or b
Response from Robert J. Frascino, M.D.
The Robert James Frascino AIDS Foundation...partner. Later i came to know that the partner was with a promiscous guy(who sleeps around with prostitutes) before me. I have got tested after 3 months after the exposure and the HIV antibody test result is negative. Can i forget about this and... Read more »
HIV DNA PCR POSSITIVE (ANOTHER FALSE POSITIVE PCR TEST, 2010)Having a sex contact with a sexs worker(-protected vaginal-unprotected oral) and because of my anxiety reading of the risk of getting the disease,even if its a low risk, ihad cause i couldn wait an DNA PCR at 6 weeks on a lab. The result came back...
Response from Robert J. Frascino, M.D.
The Robert James Frascino AIDS Foundation...Hello,As I have frequently stated in this forum, PCR testing should not be used for routine HIV diagnostic screening, due to the rate of false-positive results, technical considerations Read more »
Follow-up Question about Hep C and HIV Coinfection (DELAYED SEROCONVERSION: HIV and Hepatitis C coinfection 2009)Dear Dr. Bob,Thank you for your prompt response. I will be making a donation at www.concertedeffort.org tomorrow. I have just a couple of questions I meant to ask previously.My risk event occurred as a result of a sexual assault from a man from...
Response from Robert J. Frascino, M.D.
The Robert James Frascino AIDS Foundation...partner. Later i came to know that the partner was with a promiscous guy(who sleeps around with prostitutes) before me. I have got tested after 3 months after the exposure and the HIV antibody test result is negative. Can i forget about this and... Read more »
Bahrain -- Can I woohoooooo--Very Very UrgentDear Doctor Bob,I live in Bahrain where i have been sex with sexworkers with condoms for the last 3 years.First 1 year i used to wear a single condom and after 6-7 woman i started using double condoms.A couple of times i found blood on the outside...
Response from Robert J. Frascino, M.D.
The Robert James Frascino AIDS Foundation...on such an "urgent basis?" The only potential problem I see is that you may either become anemic or go broke from excessive testing!Dr. Bob Read more »
Viral Load Tests...test, which can be "negative" for 2 to 6 months after HIV infection. (See Fact Sheet 102 for more information on HIV antibody testing.) For prognosis , viral load can help predict how long someone will stay healthy. The higher the viral load,... Read more »
Understanding HIV-Related Lab Tests II: Viral Load, Resistance and Tropism...Viral Load Test Viral load is the amount of HIV in your bloodstream. Viral loadcan be measured by two different lab tests: polymerase chain reaction (PCR) orbranched DNA (bDNA). It is best to stick with the same kind of test and notswitch... Read more »
Understanding Genital Herpes...them consistently and correctly, but transmission can still occur since condoms may not cover all infected areas. You can get tested to find out if you are infected with the herpes virus. Complications Genital herpes infections usually do... Read more »
Women and HIV Viral Load...of HIV, the greater the risk of your immune system being damaged. Viral load can be measured by two different lab tests: a polymerase chain reaction (PCR) test or a branched DNA (bDNA) test. Both tests are accurate, but each has a different way... Read more »
Connect With Others
DNA PCR Test
Posted by Anonymous, 3 Replies...Does anyone recommend the DNA PCR test i.e. the test that looks for HIV directly rather than HIV antibodies. Does anyone have any experience of this test and Read more »
What do you think of DNA PCR tests?
Posted by Anonymous, 2 Replies...Is it wise to get a DNA PCR test done. Does anyone have any experience with this? I called a web site that offers this service and they say that this test Read more »
DNA PCR Vs Viral Load test
Posted by sunkyst, 1 Reply...Does anyone know the difference between a HIV DNA PCR test versus a viral load test that's performed on someone already confirmed positive, obviously one is about detecting the virus Read more »
Can Antibody testing, 2 DNA PCR and a P24 be wrong
Posted by Anonymous, 5 Replies...I have had the following NEGATIVE tests: Antibody Tests: 8, 10, 12, 13, 15, 17 wks Qual. DNA PCR's: 12(HIV-1, HIV-2), 15(HIV-1 Labcorp) wks P24 Antigen: 17wks Had an ARS illness, worst flu of my life almost 3 months ago and Read more »
Resource Centers
Guides for People With HIV


text:
Motel 6 Denton
No availability found through our partners. Please contact the business directly or check some of our recommended alternatives.
How has this motel rated in the past?
- Restaurant
- Swimming pool
- Free High-Speed Internet
- Restaurant
- Swimming pool
- Free High-Speed Internet
Travelers also recommend:
- More recommendations
TripAdvisor Reviews Motel 6 Denton
Travel Blogs from Denton
Just a week away
Just a week away before outer pilgrimage to Italy. We are kind of ready and kind of not. big questions: Right clothes? Too many clothes? Best walking shoes? to do: reservations to see St. Peter's tomb and the Borhese ...
Cowtown, Texas
Fort-Worth does not seem to have many air b&bs so I've booked myself into a hotel for two nights. It's cheap, like the last hotel I booked it has construction work ongoing but not too noisy. It does however have the added bonus of a gym and a pool to work of some of thanksgiving dinner. The traffic driving in was awful, I asked the receptionist if it's always this bad and he explained that it's because of the parade of lights and lighting ...
Travel to Colorado
- On the Morning of September 23 Bailey and I went to the Gas Station filled up our tank, bought ice, seeds, snacks, water, meat and bread.
- We traveled 253 miles to Gainesville, Texas, Filled up
- Gainesville, Texas traveled 137 miles to Oklahoma City, Ok, filled up
- We ate the assorted lunch meats and snacks for lunch and dinner for the ...
Van, Lisa, and Autumn Visit
... apartment. The next day they came over and swam with us before heading down to Fort Hood.
On the drive back north after the ceremony they stopped by again and met Michael and Leah down in Fort Worth at the Water Gardens. It was such a fun time and we are so lucky to have been able to see them twice in a short week.
Coach Sucks!
... doors for other people, regardless of gender. And I would relinquish my seat on a bus for an older person, male or female, or a person with a disability,
But when it comes to the lack of respect young men have for women, I don't blame feminism. I blame Girls Gone Wild. And bad parenting.
Landing at Heathrow means having to get from Terminal 5 to Terminal 3. I had hoped for time to shop, but again it was cutting it close, and my carry-on ...